Key facts
- It has raised $7.7M; the latest was Early Stage VC ($3.6M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, BMI Korea, InfoBank, KUDOS Company, Kite Entrepreneur Foundation — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Crosspoint Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Crosspoint Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Crosspoint Therapeutics
Developer of a stealth-body technology designed to reduce off-target toxicity in antibody therapies. The company's platform applies proprietary Fc-silencing mutations that markedly diminish Fc-effector functions, demonstrates no meaningful binding or activity across Fc gamma receptors, supports incorporation of these modifications into diverse antibody backbones, and is used to advance internal and partnered drug discovery programs, enabling biopharmaceutical developers and research organizations to generate next-generation antibody therapeutics with improved safety profiles, more controlled pharmacologic activity, and broader applicability for refractory diseases with high unmet clinical demand.
- Sector
- Healthcare
- HQ
- Hwaseong, South Korea
- Founded
- 2022
- Employees
- 7
- Website
- crosspointrx.com/
- Ownership
- Privately Held (backing)
Crosspoint Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Crosspoint Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Crosspoint Therapeutics in its N-PORT filings yet. We sweep new filings monthly.